S100A9 and diabetes mellitus: Therefore, as we demonstrated that increasing the circulating level of S100A9 is able to improve the metabolic imbalance caused by ID (Fig. 6C, D, I–K), our murine and human data provide scope for further increasing plasmatic S100A9 as a potential therapeutic clinical avenue in diabetes.